Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/ASO.2005.06.032
Annals of Surgical Oncology 12:422-428 (2005)
© 2005 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rivoire, M.
Right arrow Articles by Grange, J.-D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rivoire, M.
Right arrow Articles by Grange, J.-D.

Original Article

Treatment of Liver Metastases From Uveal Melanoma

Michel Rivoire, MD, PhD1,2, Laurent Kodjikian, MD, PhD3, Stefano Baldo, MD1, Pierre Kaemmerlen, MD4, Sylvie Négrier, MD, PhD5 and Jean-Dominique Grange, MD3

1 Department of Surgery, Centre Léon Bérard, 28 Rue Laennec, 69373 Lyon, Cedex 08, France
2 Institut de Recherches Chirurgicales, Unitéde Formation et de Recherche Lyon-Nord, 8 Avenue Rockefeller, 69373 Lyon, Cedex 08 France
3 Department of Ophthalmology, Hôpital de la Croix Rousse, 103 Grande Rue de la Croix - Rousse, 69317 Lyon, Cedex 04 France
4 Department of Radiology, Centre Léon Bérard, 28 Rue Laennec, 69373 Lyon, Cedex 08, France
5 Department of Medicine, Centre Léon Bérard, 28 Rue Laennec, 69373 Lyon, Cedex 08, France

Correspondence: Address correspondence and reprint requests to: Michel Rivoire, MD, PhD; E-mail: rivoire{at}lyon.fnclcc.fr.

Background: Uveal melanoma patients with liver metastases have a poor prognosis. The effect of screening and multimodality treatment (including surgery) should be evaluated.

Methods:: A total of 602 patients treated for uveal melanoma during a 14-year period had abdominal ultrasonography screening every 6 months. Sixty-three developed liver metastases as the first extraocular metastatic site. When possible, liver surgery and intra-arterial catheter implantation were performed. The influence on survival of demographics, uveal tumor characteristics, liver metastasis presentation, and treatment was studied.

Results: The median time to liver metastasis was 29 months. Twenty-eight patients (44%) were operated on: 14 (22%) had R0 liver surgery, and 14 with diffuse liver involvement had R2 liver surgery (there were no significant surgical complications). Thirty-five patients with diffuse liver involvement received systemic chemotherapy or best supportive care only. The median overall survival was 15 months (range, 3–110 months): 25 months for the 14 patients with R0 surgery, 16 months for the 14 with R2 surgery, and 11 months for the 35 with chemotherapy or supportive care. By univariate analysis, age (≤70 years), number of metastases (≤10), and quality of operation (R0) were predictive of a better prognosis.

Conclusions: In the case of liver metastases from uveal melanoma, aggressive treatment permitting tumor eradication seems to offer a chance of long-term survival to selected patients. Nevertheless, neither ultrasound screening nor quality of operation had an effect on the outcome of most patients (78%). Better screening tests and more effective multimodality treatments are required to improve survival in uveal melanoma patients with hepatic metastases.

Key Words: Uveal melanoma • Liver metastases • Liver surgery • Hepatic resection • Chemotherapy • Prognosis factors




This article has been cited by other articles:


Home page
 RadiologyHome page
A. Yamamoto, I. Chervoneva, K. L. Sullivan, D. J. Eschelman, C. F. Gonsalves, M. J. Mastrangelo, D. Berd, J. A. Shields, C. L. Shields, M. Terai, et al.
High-Dose Immunoembolization: Survival Benefit in Patients with Hepatic Metastases from Uveal Melanoma
Radiology, July 1, 2009; 252(1): 290 - 298.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
T. Meir, R. Dror, X. Yu, J. Qian, I. Simon, J. Pe'er, and I. Chowers
Molecular Characteristics of Liver Metastases from Uveal Melanoma
Invest. Ophthalmol. Vis. Sci., November 1, 2007; 48(11): 4890 - 4896.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
V. Barak, S. Frenkel, K. Valyi-Nagy, L. Leach, M. A. Apushkin, A. Y. Lin, I. Kalickman, N. A. Baumann, J. Pe'er, A. J. Maniotis, et al.
Using the Direct-Injection Model of Early Uveal Melanoma Hepatic Metastasis to Identify TPS as a Potentially Useful Serum Biomarker
Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4399 - 4402.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
R. Folberg, L. Leach, K. Valyi-Nagy, A. Y. Lin, M. A. Apushkin, Z. Ai, V. Barak, D. Majumdar, J. Pe'er, and A. J. Maniotis
Modeling the Behavior of Uveal Melanoma in the Liver
Invest. Ophthalmol. Vis. Sci., July 1, 2007; 48(7): 2967 - 2974.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P Kiewe, N. Bechrakis, A Schmittel, P Ruf, H Lindhofer, E Thiel, and D Nagorsen
Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma
Ann. Onc., December 1, 2006; 17(12): 1830 - 1834.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Society of Surgical Oncology.